Theravance Banks $100m As J&J Bets Big On IBD Drug

 
• By Kevin Grogan

If the JAK inhibitor codenamed TD-1473 proves effective in Crohn’s disease and ulcerative colitis, the clinical, regulatory and commercial know-how in IBD from partner Janssen could help Theravance pocket $1bn.

Motorcycles
Future leader of the JAK in IBD? Theravance boosted by Janssen backing • Source: Shutterstock

More from Immunological

More from Therapy Areas